Author: Editor

Bernard J. Escudier, MD introduces Dr. Cora Sternberg, MD before the P.J.M. dMulder Lecture at the 12th Annual European Kidney Cancer Meeting 2017

Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the treatment trends for lymphoma in 2017, which include targeted therapy, chemotherapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an overview of his presentation, CHRONOS-1, which shows the use of copanlisib in B-Cell Lymphoma patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC. CORRECTION: Follicular Lymphoma subset ORR was 59.7% MZL group was 69.6%

Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an update on immunotherapy, which was a hot topic of AACR 2017. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern explains the difference between copanlisib and other PI3K inhibitors, specifically Idelalisib He argues that copanlisib seems to be better tolerated in patients than Idelalisib. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the impact of his clinical trial, CHRONOS-1, on current and future cancer research. He states that the compounds of drugs are affective in any stage of disease and that the data continues to show the important roles of PI3K Inhibitors. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the treatment trends in 2017 for his field, neuro-oncology, which include more use of checkpoint inhibitors and combination therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of the AACR presentations, which show more data and focus on exosomes and blood biopsies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how intracellular targets are detected onto the cell surface. He states that this target is a protein that usually does not belong on the cell surface, but has been detected through an antibody. The uncertainty of how this target moved is part of exciting new research in glioma biology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how the clinical data will help better characterize which patients respond to immunotherapy. Specifically, this data would tell clinicians which patients respond to the survivin vaccine. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the impact his clinical trial has on clinicians and future research. He states that if they continue to build more data, then the study could potentionally predict when a patient may recur. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Circulating CD9-GFAP-survivin exosomes during active specific immunotherapy, a potential biomarker for glioma, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives her input on when patients should stop treatment. She states that if the patient shows responsive to treatment, then she would feel comfortable allowing the patient to stop early. She also explains whether or not all patients should have PD-L1 staining. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains how this clinical trial now allows clinicians and other healthcare professionals to quote five-year data to patients with non-small cell lung cancer. She argues the impact of this data will give hope to lung cancer patients of their options. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center discusses the treatment trends for 2017 in thoracic oncology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of her presentation which discussed a five-year follow-up of Lung Cancer patients, who were treated with Nivolumab. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the impact of her clinical trial on current clinicians and future research. She argues how this trial is the first trial to show a five-year survival rate for non-small cell lung cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of some of the presentations that were discussed at AACR 2017. She states that these presentations range from Merkel Cell Carcinoma to Immunotherapy for Breast Cancer and Melanoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, explains that there is a big debate on whether robots should be used for surgical procedures at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Albers highlights that the complications which are seen are different compared to open surgery, however there are great visibility advantages of robot-assisted surgery. Prof. Albers points out that there is a lack of data comparing in detail robotic and open surgery. Aspects which need to be considered when comparing robotic and open surgery include familiar parameters, such as rate of positive margins, time…

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, discusses how checkpoint inhibitors can be used earlier in bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that the current focus of immune checkpoint inhibitors in bladder cancer is in the advanced or metastatic stage. However, according to Prof. Powles, the bigger picture involves bringing these drugs into earlier disease stages. He speaks about checkpoint inhibitors which are being trialed in an adjuvant setting (CheckMate 274, NCT02632409; IMvigor010, NCT02450331) and neoadjuvant setting (NCT02451423). Prof. Powles concludes that the story of…

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, gives an overview of the use of checkpoint inhibitors in metastatic urothelial bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that the differences seen clinically with immune checkpoint inhibitor treatment, and speaks about recent clinical trial results. According to Prof. Powles, one of the next key questions which needs to be addressed is whether frontline randomized Phase III studies show improved outcomes with immunotherapy compared to chemotherapy in bladder cancer. Whether biomarkers will be important for this also needs to…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the current landscape and future direction of systemic therapy for renal cell carcinoma (RCC) at the European Association of Urology (EAU) conference 2017 in London, UK. She highlights that impressive developments have been seen in metastatic kidney cancer. She describes results from a randomized Phase II study using a combination of lenvatinib and everolimus (NCT01136733), as well as the CheckMate 025 Phase III randomized trial (NCT01668784) and Phase III METEOR trial (NCT01865747) comparing everolimus with cabozantini. According to Prof. Osanto, recent trials have revolutionized the treatment of…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical implications of circulating tumor cell (CTC) analysis in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that for patients with localized prostate cancer, there is currently no evidence that circulating tumor cells can be used in a clinical setting to monitor disease or treatment outcomes. In contrast, in patients with a higher tumor load, such as those with castration-resistant prostate cancer (CRPC) who need to undergo system treatment or in whom we know that treatment resistance has…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical utility of circulating tumor cells (CTCs) at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that this is a very powerful approach, which allows patients with metastatic disease to be tested for disease presence and the number of circulating cells, as well as the characteristics of the tumor cells. Prof. Osanto explains how circulating tumor cells can be molecularly profiled at a single-cell level.

Rong Na, MD, from the Huashan Hospital, Fudan University, Shanghai, China discusses germline mutations in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He introduces a study whose aim was to evaluate the association between germline mutations in DNA repair genes and the risk of prostate cancer, which evaluated the rate of carriers in lethal and indolent prostate cancer patients, as well as survival time. Dr Rong Na also discusses the next steps in this study.

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, discusses which factors are important to consider in surgical robots at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages presented by robot-assisted surgery and points out new imaging technologies which are only possible in laparoscopic or robot-assisted surgery. Prof. Albers argues that the future of surgery will be in a minimally invasive approach and that technical improvements are necessary to maximize the advantages of robotic surgery.

Jame Abraham, MD of Cleveland Clinic discusses his hopes for NSABP-FB10 becoming a Phase II and Phase III trial for patients with breast cancer. He also discusses how to manage the diarrhea and nausea in patients who underwent this study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic discusses the key finding from his study shows the impact of neratinib for breast cancer treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic states that although breast cancer treatment has yet to include immunotherapy, it is still dominating the field of cancer as a whole. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic discusses the treatment trends for breast cancer, which include PARP inhibitors, CDK 4/6 Inhibitors, and Immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the determinants of what allows tumor samples to be released into the blood stream. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the need for a genomic encyclopedia for radiation oncology. He argues that a genomic encyclopedia could help when deciding treatment if they already know which patients respond to certain therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses his speciality, radiation oncology, and the treatment trends he sees for 2017. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses Joe Biden’s address to AACR and the importance of receiving funding from these types of organizations for cancer genomics and research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses the impact of his panel discussion and his hopes towards the ability of extracting genomic information from these tumor samples, whether it’s through tumor sampling or liquid sampling. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic gives an overview of his panel discussion, Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

In this roundtable discussion, Drs. Gerald Prager, Tanios Bekaii-Saab, and Eric Van Cutsem examine the safety and efficacy profiles of the available agents for patients who have failed first- and second-line therapy, provide insight into how to manage adverse effects, and elucidate how best to incorporate said agents in the appropriate sequence, either in combination or alone, when they are available. Earn CME Credit for this activity: http://bit.ly/2lzM53l

In this Key Insights activity, Dr. Scott Kopetz and conference chair David H. Ilson discuss the key non-colorectal cancer-related take-home messages from the 2017 Great Debates and Updates in Gastrointestinal Malignancies conference held March 24-25, 2017 in New York. Earn CME Credit for this activity: http://bit.ly/2oeonuL

In this Key Insights activity, Dr. Scott Kopetz and conference chair Axel Grothey discuss the key colorectal cancer-related take-home messages from the 2017 Great Debates and Updates in Gastrointestinal Malignancies conference held March 24-25, 2017 in New York. Earn CME Credit for this activity: http://bit.ly/2oeokiz

Recorded on site during the 18th European CongressL Perspectives in Lung Cancer, this activity features conference chairs Giorgio V. Scagliotti, MD, PhD and Luis Paz-Ares, MD, PhD discussing the key take-home points from the meeting. Earn CME Credit for this activity: http://bit.ly/2oyBiZv

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of MRI in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Emberton explains that MRI allows the cancer to be identified, described, characterized and biopsied better, and will hopefully in future allow it to be treated better. He describes the PROMIS study (NCT01292291), and highlights that at EAU 2017, the ramifications of these data are just being explored. He concludes that MRI in prostate cancer offers more opportunity, fewer and better biopsies, better risk stratification,…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the joint meeting of the EAU and Japanese Urological Association at the European Association of Urology (EAU) conference 2017 in London, UK. European and Japanes uro-oncologists discussed the best second-line treatment in advance metastatic renal cell carcinoma (RCC).

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the limitations of magnetic resonance imaging (MRI) in prostate cancer diagnosis at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that MRI can be used as a triage test in patients with suspicion of prostate cancer who have not yet had a diagnostic workup for prostate cancer. Some studies have described that if an MRI is negative in this case, there is no need to worry about the presence of significant cancer, while others have observed that significant cancer can be missed when using this…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the currently available androgen deprivation therapies (ADT) at the European Association of Urology (EAU) conference 2017 in London, UK. He argues that an important factor is which ADT is used, as they have different mechanisms of action and response times.

Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses results from the ProtecT trial in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. This Phase III prospective randomized clinical trial evaluated the efficacy of different treatment modalities in low and intermediate risk prostate cancer. He outlines the data presented at EAU 2017, which focused on histological features of tissue from patients in the ProtecT trial. Discriminating between patients that progressed and those that did not, pathophysiology was retrospectively assessed in biopsy tissue, as well as the entire prostate if surgery was carried out. He explains…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, speaks about highlights from the session on advanced prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He says that there was a lot of discussion about advanced prostate cancer, such as what to do with lymph node recurrence after prostatectomy if cancer is found in a small number of lymph nodes in the pelvis after a period of remission. A subsequent presentation covered the complications of this procedure. The session also covered systemic therapy in metastatic castration-resistant prostate cancer, and Prof. Merseburger highlights a study…

Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses clinical trials of robotic surgery in radical cystectomy at the European Association of Urology (EAU) conference 2017 in London, UK. According to Prof. Brausi, the most important randomized trial in robotic surgery for radical cystectomy is a Phase III study carried out at the Memorial Sloan Kettering Cancer Center in New York, NY (NCT01076387). Prof. Brausi summarizes the results of the trial, and concludes that robotic surgery for muscle invasive bladder cancer shows promise but is not yet the standard.

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of videos to communicate science at the European Association of Urology (EAU) conference 2017 in London, UK.

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the advantages of using imaging information for prostate cancer diagnosis and management at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Walz explains that prostate cancer, according to EAU guidelines, is currently diagnosed by randomized biopsy without using imaging information to target the tumor. Several technologies are available to promote the use of imaging information in prostate cancer diagnosis. Reliable imaging will allow decisions to be made on whether a cancer needs to be treated or followed by active surveillance. He concludes that the use of…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, gives an overview of checkpoint inhibitors for urothelial carcinoma treatment at the European Association of Urology conference 2017 in London, UK. Immunotherapy has been developed in patients with advanced disease failing first- or second-line treatment. Dr Bellmunt explains that based on the results seen, immunotherapy is now being moved to earlier phases of the disease and as a first-line treatment in patients with metastatic disease, patients ineligible for chemotherapy, or in an adjuvant or neoadjucant setting. Looking forward, Dr Bellmunt explains that biomarkers are being identified which will allow…

In this presentation from Lymphoma & Myeloma 2016, Dr. Kelly M. Trevino discusses strategies to focus on quality of life when choosing a lymphoma therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson argues for the use of novel agents for a 60 year patient with follicular lymphoma who has relapsed less than two years after receiving upfront R-CHOP therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. David G. Maloney argues for stem cell transplant for a 60 year patient with follicular lymphoma who has relapsed less than two years after receiving upfront R-CHOP therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson discusses the latest novel agents for the treatment of follicular lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Jia Ruan discusses the most promising new approaches and agents for the treatment of T cell lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Kieron Dunleavy discusses the latest developments in the upfront and relapsed treatment settings of primary CNS lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Sonali M. Smith discusses whether or not one should utilize cell of origin and “double protein” expression in the treatment of diffuse large b-cell lymphoma (DLBCL). Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. George P. Canellos discusses the past, present, and future of Hodgkin disease. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

How should we approach the adolescent/young adult Hodgkin lymphoma patient? Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses developments in prostate cancer presented at a video session at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that prostate fusion biopsy, which combines MRI and ultrasound imaging, is becoming more readily available, and comparable to biopsy carried out in the MRI apparatus. Prof. Stief points out that fusion biopsy is cost effective and much easier for patients to endure, while also giving precise information on the tumor itself and the extent of the tumor. He also speaks about cryotherapy, where a specific spot undergoes cryotherapy right…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the use of social media in uro-oncology at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that using Twitter for just 15 minutes a week allows him to keep up to date with the latest news from conferences. Prof. Merseburger believes that Twitter is a good resource; it does not replace face to face meetings or conferences, but if someone is not able to go to a conference, Twitter allows them to get fast and immediate information on what is happening in their peer group.

Drs. Jared Weiss, Assistant Professor, Clinical Research Hematology/Oncology, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, join GRACE to discuss updates relating to pembrolizumab, nivolumab and PD-L1 markers for head and neck cancers.

From our MPN Ask the Expert series, Patient Power viewer, Maryse, asks a question about the MPL mutation and if there are targeted treatments being developed for this mutation. Dr. Prithviraj Bose from The University of Texas MD Anderson Cancer Center responds by explaining the MPL mutations as it relates to others like JAK2 and CALR and goes on to discuss treatments that are meant to target the JAK-STAT pathway. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, summarizes the aims and results of the KEYNOTE-045 (NCT02256436) trial of pembrolizumab as a second-line agent in the treatment of urothelial carcinoma at the European Association of Urology conference 2017 in London, UK. He explains that this Phase III randomized trial was carried out in patients failing first-line platinum-base chemotherapy, or second- or third-line chemotherapy in some cases. Patients received pembrolizumab every three weeks, or standard of care chemotherapy (paclitaxel, docetaxel, or vinflunine). Dr Bellmunt highlights that this is the first trial showing an advantage of immunotherapy over chemotherapy…

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains the use of genomic profiling for prognoses in breast cancer, which shows the chances of relapse and a prediction for endocrine therapy or chemotherapy. He states that with genomic profiling, oncologists can tailor their treatments based on these results. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses the treatment trends in 2017 for estrogen receptor positive breast cancer, which include the use of CDK46 inhibitors. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses current clinical trials and genomic profiling in breast cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic

Shaji K. Kumar, MD of Mayo Clinic gives an overview of the upcoming treatment trends for multiple myeloma, which include combination therapy after relapse, longer duration of treatment, early intervention, and clinical trials development. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic discusses how to gain a better understanding in treating multiple myeloma. He states that most patients who are treated end up relapsing, so oncologists need to figure out why they continue to relapse and how does the disease evolve over time. Ultimately, oncologists need to concentrate more on the biology of the disease to better treat patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic CHANGE TITLE–Myeloma

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School explains whether or not somatostatin analogues were needed to see efficacy in treatment for carcinoid syndromes. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School gives an overview of his discussion, Novel Treatment Options for Neuroendocrine Tumors, which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School discusses the results of the NETTER-1 study, which concluded with patients who were treated with octreotide had significantly improved progression free survival compared to patients who were not treated with the drug. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains what to do with patients who have neo-adjuvant chemotherapy and how the response to chemotherapy affects the radiation oncologist’s decision on what should be treated or not. She states that based on the guidelines, the role of radiation is defined by the maximal disease stage. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? stresses the importance of tailoring treatment options to patients’ specific risks. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses the role for regional nodal irradiation in breast cancer treatment. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of the new radiation guidelines for treating patients with breast cancer. She states there are several evolving treatment options and to communicate with patients which options work best for them. She stresses the importance of tailoring those treatment options to the patients’ individual needs and desires. 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains how to select effective radiation options for breast cancer treatment. She argues that more treatment is only better if it benefits the patient in the long-run, and ultimately, she is learning that sometimes, more is not always better in select patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of her presentation, “Evolving Radiation Therapy Recommendations for Breast Cancer,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses treatment trends in 2017 for breast cancer treatment. She states that many parts of breast cancer management is gravitating towards less radiation and how to use neo-adjuvant chemotherapy to assess next treatments. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the types of evidence that the National Comprehensive Cancer Network (NCCN) look for when it comes to their guidelines. He states that the NCCN panel is looking for data from not only clinical trials, but other complementary sources of data. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns over patient affordability with cancer care. He argues that the separation between the level of quality in cancer care and what the patient can afford is widening. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of another theme from his session, which was disparities in cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the National Comprehensive Cancer Network’s (NCCN) guidelines program and the addition of the evidence blocks. He states that the evidence blocks have an element of affordability, which provides an opportunity for oncologists and other health care professionals to talk with patients about costs. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses themes of his session, which included concerns over cutbacks for the National Institute of Health (NIH). He states that we need continuity in funding of cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns about a rollback in coverage, losses in preventive services, and affordability in cancer care, which were covered at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of the new staging system by the American Joint Committee on Cancer (AJCC). This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses questions he received from the audience, one being whether or not the staging system is becoming too complicated. He answers yes, it is getting more complicated and more confusing, but at the same time, this will overall improve the value of staging. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of his presentation “Implications of the New AJCC Staging System,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute explains how health care disparities have become a critical issue and an area of discussion at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the importance of personalized medicine, specifically genomic profiling in breast cancer. He states that with more use in genomic profiling, chemotherapy has decreased in need. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the American Joint Committee on Cancer (AJCC) and its collaboration with Union International Cancer Control (UICC) for global use, where patients can be compared across the globe. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Jennifer Young Pierce of Medical University of South Carolina at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center discusses the importance of communicating the safety and efficacy of the HPV vaccine with other healthcare professionals, primary care physicians, and families. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of an HPV-related abstract that was discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. She states that the abstract argued the importance of the vaccine in preventing around 6 different types of cancer (vaginal, penile, vulvar, cervical, anal, oropharyngeal).

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Lois Ramondetta of MD Anderson Cancer Center at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the practical guidelines for gynecologic oncologists in getting involved with the HPV vaccine outreach. She lists talking with physicians about the vaccine’s role in cancer prevention, introducing survivors, and working with local cancer facilities as just a few approaches. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina discusses the importance of spreading HPV vaccine awareness, especially the data that shows the impact of the vaccine in cancer prevention. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the treatment trends for the HPV vaccine in 2017. One specific treatment trend is to go from a 3 dose regiment to a 2 dose for regiment for the vaccine, which allows increase completion rates since it can be difficult for patients to come back for the third dose. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses the treatment trends for ovarian cancer for 2017. She highlights the use of FDA-approved PARP inhibitors, immunotherapy, and even combination therapy with PARP inhibitors and immunotherapy. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center explains why it is crucial to use both germline and tumor testing instead of completely skipping germline testing. She states that if clinicians skip the initial germline testing, 10% of BRCA 1 mutations will be missed. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses development of more efficient clinical tests that will accurately predict which patients respond to PARP inhibitors. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center gives an overview of a second presentation that discussed the ARIEL2 Trial at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. From the presentation, the data concluded that the patients who developed platinum-resistance were less likely to respond to the drug. She argues clinicians need to introduce the drug earlier in treatment so patients don’t develop resistance.

Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but other cancers as well. She states that ovarian cancer is the leading factor in the field of PARP inhibitors and what is learned in ovarian cancer can be applicable to other cancers. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Ruben A. Mesa, MD of Mayo Clinic discusses questions from the audience that were asked during his session on the new guidelines for myeloproliferative neoplasms. He states that overall quality has become the main focus for these guidelines. This was recorded at 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the upcoming treatment trends for myeloproliferative neoplasms, which include new FDA approved agents, JAK inhibitors, and combination studies. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of interesting topics, such as health disparities and access to care, which were discussed at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic explains the importance of the NCCN and its development of new guidelines for cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the new guidelines that are set for leukemia. He states that guidelines ultimately help to identify key areas of unmet needs, specifically drivers in the spectrum of chronic leukemia toward acute leukemia. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Saketh Guntupalli, MD of University of Colorado School of Medicine gives an overview of the kinds of treatment trends for 2017 in his specialty. He states that as a clinician and a surgeon, he hopes to improve the quality of surgeries by finding an easier way to prevent complications, such as blood clots, from happening. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine explains how patients were picked for his clinical study and their responses to the trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses the importance of his study and how he hopes that the increase of compliance with medication can help prevent blood clots and other bleeding risks in the future. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine gives his take on how women can deal with their intimate relationships after a cancer diagnosis. He states that this is an area of less interest in cancer survivorship, thus women and clinicians should openly communicate about these kinds of issues. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses interesting topics that were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. He states that there is a new focus on molecular therapeutics in women with cancer, which acts more specifically and effectively in patients.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses the data of his presentation, which was a randomized trial of oral apixaban and subcutaneous enoxaparin for prevention of blood clots and VTEs in patients with gynecologic malignancies. Data concluded with more risk of bleeding in patients who took a pill than in patients who had blood thinning injections. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, gives an overview of the KEYNOTE-052 (NCT02335424) trial of pembrolizumab in urothelial bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. This Phase II trial is investigating pembrolizumab treatment in urothelial bladder cancer patients ineligible for cisplatin-based chemotherapy. Prof. Powles explains that historically, the majority of patients in this setting have been treated with chemotherapy, and cisplatin is the standard approach in this case, however a substantial proportion of patients are not fit enough or have insufficient renal function for this treatment. Pembrolizumab…

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, discusses the concept of a semi-live surgical masterclass at the European Association of Urology (EAU) conference 2017 in London, UK. He says that this new format has been introduced in surgical education across disciplines over the past few years. Prof. Albers explains that the for a semi-live masterclass, a live surgical procedure is videotaped, and this video is brought to the presentation, and discussed with other presenters, typically comparing different techniques for carrying out a specific procedure, such as anastomosis. An advantage of the semi-live approach is that techniques can be demonstrated…

Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses the use of robotic surgery for urological cancers at the European Association of Urology (EAU) conference 2017 in London, UK. He describes the joint session with ERUS, the EAU Robotics section, where kidney, bladder and prostate cancer surgery were debated, comparing open surgery with robotic surgery. Prof. Brausi explains that results are good, both with open and robotic surgery. Taking prostate cancer as an example, oncological results do not differ significantly between the different surgical approaches, however robotics is superior when assessing quality of life, erectile dysfunction…

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the use of magnetic resonance imaging (MRI) in targeting prostate cancer biopsy at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that magnetic resonance imaging (MRI) is currently the most well evaluated tool for prostate cancer diagnosis, and many studies are evaluating this imaging approach. Current recommendations are that an MRI should be carried out before a repeat biopsy, if a suspicion of prostate cancer persists after a negative randomized biopsy. Repeat biopsies identify cancer in 20 25% of cases. By using imaging as additional…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses recent advances in treating genitourinary malignancies at the European Association of Urology conference 2017 in London, UK. Focusing on immune-oncological agents in bladder cancer, the first-line treatment in patients with metastatic disease is platinum-based chemotherapy, with second-line therapy until recently also being chemotherapy-based, with only vinflunine approved in Europe. In the US, additional second-line agents were used, such as paclitaxel and docetaxel, however limited benefit was seen for patients with these. Recent advances in immune-oncological agents mean that this is now an option for bladder cancer treatment, with…

From our MPN Ask the Expert series, Patient Power viewer, Barb, asks a question about peripheral neuropathy as a side effect of treatment for essential thrombocythemia (ET). Dr. Prithviraj Bose from The University of Texas MD Anderson Cancer Center responds by suggesting treatments that do not cause neuropathy and options for reducing the effects of neuropathy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Susan C. Modesitt, MD of University of Virginia Health System gives an overview the hot topics and trends that were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System discusses the treatment of sentinel lymph nodes, which unintentionally cause isolated tumor cells. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System explains whether or not hospital readmission is an appropriate marker for quality of life. She argues that it may not be the right metric for success. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System discusses the use of PARP inhibitors and their benefits towards treating women with ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses how the use of PARP Inhibitors work for Ovarian Cancer treatment without BRCA mutations. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses the use of PARP Inhibitors and in combination with Anti-VEGF, Chemotherapy, and Immunotherapy Agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC explains why the use of molecular analysis to determine therapy choice is more of a hope to society. He argues that it is not ready for clinical use and discusses the current NCI-MATCH trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses novel agents, Olaparib and Rucaparib, that target BRCA mutations in Ovarian Cancer. He also states that even in patients who did not have any mutation still showed great therapeutic responses from the agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses data that argued how platinum sensitivity was an important predictor for Rucaparib response. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital gives an overview of the treatment trends for 2017 in ovarian cancer treatment, which were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital gives an overview of the SOLO2 Trial and the use of olaparib in ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses the use of novel agents in ovarian cancer. He states that Olaparib and Rucaparib are not FDA approved for clinical trials but are approved for use as a line of treatment for patients who succeeded with chemotherapy but relapsed. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses the use of immunotherapy in cervical cancer treatment. He explains a clinical trial where an HPV protein was used for treatment and although there was a low response rate, there was overall improvement of over 50%. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Learn more about personalized medicine, also known as precision medicine, in this web interview with Patient Power Host Andrew Schorr and Dr. Razelle Kurzrock, Director of the Center for Personalized Cancer Therapy at UC San Diego. Dr. Kurzrock explains what needs improvement in cancer therapies, next-generation sequencing, combination therapies, and what patients can do to understand the complex data. Dr. Kurzrock is a pioneer of personalized medicine, and in this replay she goes into detail on how doctors are using advanced technology to look at the combinations of available treatment to see what applies to an individual. Get email alerts…

Christina Annunziata, MD, PhD of National Institutes of Health discusses how some novel agents may meet the guidelines for accelerated approval in phase 2-3 design trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health explains how the phase 2-3 design decreases the number of patients required to deliver results of clinical trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health discusses how to take a drug from phase 1 to phase 3. She explains further on how the drug needs to be targeted to the patient with the right marker. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health discusses how future research will be affected by clinical trials. She argues the results of clinical trials will guide future therapy for patients. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

MPN experts, Dr. Michael Grunwald from Carolinas HealthCare System’s Levine Cancer Institute and Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center, share insights on the purpose of the bone marrow biopsy and how the test affects overall care and treatment decisions. Each expert weighs in on how they monitor patients in their own practice, including why and how frequently their patients are tested. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Philip McCarthy, MD, Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute in Buffalo, NY, shares benefits of lenalidomide maintenance therapy for multiple myeloma patients.

Amrita Krishnan, MD FACP Director, Professor of Hematology/Hematopoietic Cell Transplantation gives an update to Multiple Myeloma Research at the MOASC Oncology Summit.

Przemyslaw Twardowski, M.D., Clinical Professor of Medical Oncology, Director, Genitourinary Oncology, City of Hope Cancer Center and David Quinn, MBBS., Ph.D., Section Head, Genitourinary Oncology, Medical Director, USC Norris Cancer Hospital, University of Southern California have a discussion on prostate cancer management at the MOASC Oncology Summit.

Sybil R. Green, JD, RPh, MHA talks about MACRA Rules are Final: Time to Implement the Quality Payment Program at the MOASC Oncology Summit.

James Suh, MD, Senior Pathologist and Associate Medical Director, Laboratory Director, Research Triangle Park, NC discusses the Comprehensive Genomic Profiling: Key Insights for Patient Care at the MOASC Oncology Summit.

At a recent MPN town meeting, Dr. Jigar Trivedi, Clinical Pharmacist Coordinator, Department of Pharmacy at Carolinas HealthCare System’s Levine Cancer Institute, shared insight for patients. Dr. Trivedi discusses dosing and how medications are processed in the body, affecting each person differently. He also explains drug interactions and nurse, Erin Blackwell, stresses the importance of communication with your healthcare team about what youre taking. Watch now to find out how a conversation with a pharmacist can benefit your care. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow…

David Spetzler, PhD, President and Chief Scientific Officer, Caris Life Sciences discusses Caris Molecular Intelligence® Evidence-Guided Molecular Analysis Services at the MOASC Oncology Summit.

Karen Reckamp, MD, Medical Director, Clinical Research, City of Hope Comprehensive Cancer Center discusses The Role of Utilizing Next Generation Sequencing Diagnostics in the Treatment of Lung Cancer at the MOASC Oncology Summit

Edward B. Garon, MD, MS, Director of Thoracic Oncology, David Geffen School of Medicine at UCLA discusses Personalizing lung cancer therapy in the era of next generation sequencing, targeted therapies, and emerging immunotherapies at the MOASC Oncology Summit

In this presentation from Lymphoma & Myeloma 2016, Dr. Robert W. Chen argues in favor of the use of allogeneic stem cell transplant for a Hodgkin lymphoma patents who relapses after autologous stem cell transplant. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Alison Moskowitz argues in favor of the use of serial novel agents (including brentuximab and checkpoint inhibitors) for a Hodgkin lymphoma patents who relapses after autologous stem cell transplant. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Koen van Besien argues for stem cell transplant-based therapy in the treatment of a limited stage Hodgkin lymphoma patient who remains PET positive at the end of chemotherapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Ann S. LaCasce argues for radion therapy in the treatment of a limited stage Hodgkin lymphoma patient who remains PET positive at the end of chemotherapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Leandro Cerchietti discusses novel therapeutic strategies for B cell lymphomas. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. David Weinstock discusses new targets in peripheral T cell lymphomas. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Treon discusses new insights into the biology and treatment of Waldenström Macroglobulinemia. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Swaminathan P. Iyer discusses novel agents in the pipleine for the treatment of chronic lymphocytic leukemia (CLL) and lymphoma. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. John N. Allan provides an update on Richter’s syndrome. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Neil E. Kay discusses optimal approaches for the management of chronic lymphocytic leukemia (CLL) patients with deletion 17p. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

Stephen J. Russell, MD, PhD of Mayo Clinic discusses how viral therapy results will trigger a race to complete clinical trials. He states that there has been an increase in clinical trials due to viral therapy emerging as an important combination therapy in immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen J. Russell, MD, PhD of Mayo Clinic explains why viral therapy may prove to be a transformational addition to immuno-oncology. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct to checkpoint immunotherapy. Both have shown impressive activity in pre-clinical models and clinical studies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute discusses how stress reducing beta blockers combined with immunotherapy may increase response rates in cancer patients. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute explains how patients on beta blockers may do better with immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute gives an overview of her presentation that was presented at ASCO-SITC Symposium. Her presentation focused on mild stress in mouse models, specifically thermal stress, which mirrors stress in humans. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Graham P. Pawelec, PhD of Universitätsklinikum Tübingen explains how new data suggests immunosenescence may not be a factor in immunotherapy treatment. Immunosenescence suggests that older people have an immune system that does not work quite as well as the immune system in younger people. He states that this is a relatively unexplored area in cancer research, but could explain why some patients’ response rates are lower than others. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of combination strategies in treatment for negative breast cancer. Specifically, in a study that combines pembrolizumab and radiation, it shows great promise for the future of combination therapy in breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the most interesting research she has seen at the ASCO-SITC Symposium. This presentation explained the effects of a microbiome as a predictor of response to checkpoint blockade strategies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center gives an overview of a poster discussion that was presented at the ASCO-SITC Symposium. This discussion described the results of a randomized study where docetaxel is used with or without plinabulin for patients with non-small cell lung cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses a Phase 1 Study that was being presented at ASCO-SITC. This study combines Carboplatin, Paclitaxel, and an HPV vaccine in the therapeutic setting. She states that even though it is a provocative and early study, the data shows great promise. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of checkpoint blockade in breast cancer. With the biomarker PDL-1, there has been a 19% response rate in women with triple negative breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking at tumor microenvironment. He mentions a study that showed patients who received standard of care therapy plus immunotherapy had a better response rate than those who only received standard of care. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses the new research regarding immunotherapies. He states that specifically in colorectal cancer, healthcare professionals are including combinations of vaccines and chemotherapy for treatment. Other treatments include vaccines and checkpoint inhibitors. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health gives an overview of the new and upcoming trends of 2017 for immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering talks about the different types of combinations in immunotherapy. She suggests that two combined treatments are better than one in overcoming resistance. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma, especially since there is a 20% response rate. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the importance of novel combinations for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab. This combination therapy is FDA approved for Melanoma, but combination therapies like these may be used for treating new cancers such as Lung, Bladder, and Kidney. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco explains how there are several combination therapies to study, but not enough patient-participants for these clinical trials. He hopes for a more rational path regarding patients in order to see which combination therapies will work. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA approved and used in clinical practice at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how immunotherapy is expanding for cancer treatment into new cancer diseases, especially ones that are more challenging to treat. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego states that in 2017, we will see more combination immuno-therapy for cancer treatment. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how biomarkers and combination therapy may be the path ahead for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC. He states that the conference focuses on the new and upcoming research and data in immuno-oncology, such as a new PDL-1, Avelumab. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the abstracts and new data that were presented at the second oral session for ASCO-SITC. The research focused on mutations in tumor and how those affects patients’ responses to treatment. This was recorded ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the promising and exciting new results from CAR T-Cell data for treatment of not only mesothelioma but other difficult-to-treat diseases. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the geographical barriers for cancer survivorship. In these undeserved areas, which are mostly rural, these patients have circumstances that are hard for most to understand. He hopes that at ASCO, more people will become aware of these barriers. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses his presentation “Driving Survivorship Home,” which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center explains how he finds patients for his Mobile Survivorship program. He states that he works with community oncologists, nurse practitioners, and public health clinics for outeach. He hopes to work with anyone who wants to work with them, and that his program will work around the patients’ needs and wants in order for them to have the best outcome. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the advantages of a mobile survivorship program. He states that there are 9 counties in Dallas, Texas where 55% of these areas are “medically underserved,” resulting in the creation of the Mobile Survivorship Program. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses the research he found most intriguing at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses how radiation has changed for invasive bladder cancer treatment. He explains the new and exciting research on biomarkers and its use for figuring out which patients will benefit from radiation therapy of bladder cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses which patients with low-risk prostate cancer should receive radiation. He argues that radiation may not be for every patient and doctors should discuss all the options that are available to their patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University explains the difference between the side effects of radiation and surgery/active surveillance and which treatment impacts a prostate cancer patient’s quality of life (QOL). This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University diseases how the use of radiation has been adopted in the treatment for advanced prostate cancer. This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University gives an overview of his presentation “Best of Journals: Prostate Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains his perspective on how to integrate drugs into treating patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how treatment for prostate cancer has changed since the emerging data on resistance. Based on his knowledge of the disease, he believes that prostate cancer will inevitably evolve to resistance. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how and when immunotherapy will be used for metastatic prostate cancer treatments at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses how the clinical trials, CHAARTED and STAMPEDE, have impacted his treatment for patients with metastatic hormone sensitive prostate cancer. He states that his patients who received chemotherapy from the study are doing remarkably well and are one step closer to eliminating the entire disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses when and where does chemotherapy fit into treatment for prostate cancer. He argues that chemotherapy should be used earlier in the disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why he believes that all metastatic castration-resistant prostate cancer patients should receive chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida. Who are the right metastatic castration-resistant prostate cancer patients that should be treated with chemotherapy

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why BRCA 1 and BRCA 2 genetic testing should be added to the guidelines for treating prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains what the biggest challenges are in facing patients and providers in the diagnosis and treatment strategies for patients with metastatic renal cell carcinoma. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses how immunotherapies are being integrated renal cell carcinoma treatment. She states that immunotherapy currently is in second or third line after targeted therapy, but is becoming more of a frontline therapy treatment for kidney cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains why chemotherapy has no role for patients with kidney cancer. She argues that targeted therapy and immunotherapy are now mostly used for kidney cancer treatment. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses the research that she thought was most intriguing at Annual Meeting GU. She states that immunotherapy has been the most exciting topic presented. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

At Patient Power’s 2016 town meeting at Levine Cancer Institute in Charlotte, Dr. Srdan Verstovsek explains why MPNs cause night sweats. Dr. Verstovsek discusses the reason symptoms are associated with this systemic disease and how doctors try to counteract those symptoms, including targeting inflammation and cell growth. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how emerging data on resistance has changed treatment for advanced prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how CHAARTED and STAMPEDE impacted his treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how and where chemotherapy fits into treating patients with prostate cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center gives his take on which metastatic castration-resistant prostate cancer patients should be treated with chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how BRCA1 and BRCA2 genetic testing are significantly changing how prostate cancer should be treated. He believes that guidelines are a bit premature, but nonetheless, they are helping with therapy options for patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas discusses the medical benefits of finding and nourishing hope, which help patients deal with their uncertainty. She defines hope as a pleasant feeling linked to the belief that the desired outcome can happen. Ultimately, hope is a shared mission, and doctors can help patients by sharing their own hopes for them having the best possible outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas advises on how to focus on hope for the best clinical outcomes for patients. She believes that hope is a feeling that is based on a belief of a future outcome. Patients are basing their beliefs on what doctors show them, which are stories, impressions, and facts that are based on a reality. If doctors succeed in providing these truths, then hope should naturally occur in patients, and that is the best outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas explains why there is no one or right approach to survivorship. She states that in order to treat all patients, doctors have to help each patient individually. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses potential approaches physicians should consider when treating metastatic non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the efficacy of pembrolizumab treatment in advanced mucosal melanoma, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This type of melanoma develops for unknown reasons unrelated to UV light exposure, and historically has a lower response rate and overall survival (OS) following various treatments. The development of new melanoma treatments, particularly immunotherapy, led Dr Butler to investigate the efficacy of these in mucosal melanoma by combining the results from the KEYNOTE-001 (NCT01295827), KEYNOTE-002 (NCT01704287), and KEYNOTE-006…

Patrick Miqueu, PhD, from the Jules Bordet Institute in Brussels, Belgium, describes a pilot project to improve the collaboration and communication between cancer patient organizations and hospitals, recorded at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes how together with the European Cancer Patient Coalition (ECPC) and Organisation of European Cancer Institutes (OECI), the Jules Bordet Institute aims to develop a minimalist model of fostering collaboration which can be applied in different European countries with existing frameworks. The project focusses on the atmosphere in cancer centers, developing a model which will be…

Lydia Makaroff, PhD, from the European Cancer Patient Coalition, introduces the coalitions new position paper, The Value of Innovation in Oncology, at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The European Cancer Patient Coalition represents more than 400 cancer patient organizations across Europe. Dr Makaroff describes the new position paper, which contains cost effective and pragmatic recommendations for European institutions and EU member states to ensure cancer patients throughout Europe have access to innovative care, technologies and treatments. The European Cancer Patient Coalition recommends that the assessment of cost effectiveness within Europe should…

Scott Murray, MD, FRCGP, FRCP Edin from the University of Edinburgh, Edinburgh, Scotland, discusses the talk he gave on different features of palliative care at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He highlights three important aspects. Firstly, palliative care needs should be identified as early as possible, starting at diagnosis, and services should be available within the community. Secondly, an assessment of the patients well-being should be made, including not just physical, but also psychosocial, social and existential issues the patient may be experiencing. Thirdly, a plan should be made together with…

Richard Neal, MB, ChB, PhD, FRCGP, from the Leeds Institute of Health Sciences, Leeds, UK, discusses his talk on reducing diagnostic delay for better cancer outcomes, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes that early diagnosis is associated with better cancer outcomes, and suggests that health care systems with a slower diagnosis process can learn from countries with faster diagnosis, resulting in better outcomes. Prof. Neal highlights three ways in which earlier diagnosis can be achieved. Firstly, patients should be encouraged to visit their healthcare practitioner when…

Katsuo Usuda, MD, PhD, from Kanazawa Medical University, Ishikawa, Japan argues that diffusion-weighted magnetic resonance imaging (DWI, MRI) will soon replace PET-CT for lung cancer diagnosis at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He discusses the benefits of diffusion-weighted MRI, which is not only cheaper than PET-CT, but also does not expose the patient to radiation.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how hopeful he is when it comes to treating non-metastatic renal cell carcinoma patients with adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses which non-metastatic renal cell cancer patients should receive adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are changing the way bladder cancer subtypes are being treated at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are helping us understand heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of University of North Carolina at Chapel Hill School of Medicine discusses his presentation, “Urothelial Carcinoma: Year in Review,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives his take on the most promising data coming out of the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses presentations he found interesting at the symposium, specifically David J. McConkey’s keynote lecture “Urothelial Carcinoma: Emerging Impact of Genomics on the Clinical Management of Bladder Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of the upcoming treatment trends for genitourinary cancers in 2017, which were discussed at the Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses his presentation, “Orphan Cancers with Opportunities for Improved Treatment (ARS)” and how his data will affect clinicians in the same field at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of his presentation “Orphan Cancers with Opportunities for Improved Treatment (ARS),” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

James Brugarolas, MD of UT Southwestern Medical Center gives an overview of the new kidney cancer research that was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

James Brugarolas, MD of UT Southwestern Medical Center discusses the use of targeted therapies in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives an overview of the new research that was discussed regarding prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when it comes to their difference in side effects for patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford discusses the how surgery, radiation, and active surveillance arms of the ProtecT study differ in terms of overall survival and metastasis free patients at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford discusses the results of the ProtecT study, which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives an overview of how the ProtecT study was designed for prostate cancer research at 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how immunotherapies are being integrated into treatment for renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center gives an overview of how targeted therapies are being used in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center discusses what approaches should physicians consider when treating patients with metastatic non-clear renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center discusses the use of adjuvant therapy to treat patients with non-metastatic renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.